Filter

Refine by date

—

Refine by collections

  • Print
  • Save

Search Results

You are looking at 1 - 10 of 60 items for :

  • Recombinant human TSH x
Clear All
C. Daumerie Departments of Endocrinology, Université catholique de Louvain, University Hospital St-Luc, Brussels, Belgium

Search for other papers by C. Daumerie in
Google Scholar
PubMed Close
,
A. Boschi Departments of Ophthalmology, Université catholique de Louvain, University Hospital St-Luc, Brussels, Belgium

Search for other papers by A. Boschi in
Google Scholar
PubMed Close
, and
P. Perros Department of Endocrinology, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Search for other papers by P. Perros in
Google Scholar
PubMed Close

exacerbation of GO and use of recombinant human TSH (rhTSH) was suggested in 2005 by Berg et al. [ 1 ], who reported the development of severe GO in a patient with disseminated thyroid cancer treated with recombinant TSH, radioiodine and retinoic acid. Multiple

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000338038
Volume/Issue:
Volume 1: Issue 2
Free access
Birte Nygaard Departments of Endocrinology, Herlev University Hospital, Herlev

Search for other papers by Birte Nygaard in
Google Scholar
PubMed Close
,
Lars Bastholt Department of Oncology, Odense University Hospital, Odense, Denmark

Search for other papers by Lars Bastholt in
Google Scholar
PubMed Close
,
Finn Noe Bennedbæk Departments of Endocrinology, Herlev University Hospital, Herlev

Search for other papers by Finn Noe Bennedbæk in
Google Scholar
PubMed Close
,
Tobias Wirenfeldt Klausen Departments of Haematology, Herlev University Hospital, Herlev

Search for other papers by Tobias Wirenfeldt Klausen in
Google Scholar
PubMed Close
, and
Jens Bentzen Departments of Oncology, Herlev University Hospital, Herlev

Search for other papers by Jens Bentzen in
Google Scholar
PubMed Close

avoid the THW-induced decrease in QOL, the use of recombinant human thyrotropin (rh-TSH) has been suggested, and several studies have confirmed that the use of rh-TSH is comparable to endogenous TSH stimulation induced by L-T 4 THW. rh-TSH is therefore

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000354803
Volume/Issue:
Volume 2: Issue 3
Free access
Tanvir Rizvi Nuclear Medicine Division, Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Va., USA

Search for other papers by Tanvir Rizvi in
Google Scholar
PubMed Close
and
Patrice K. Rehm Nuclear Medicine Division, Department of Radiology and Medical Imaging, University of Virginia Health System, Charlottesville, Va., USA

Search for other papers by Patrice K. Rehm in
Google Scholar
PubMed Close

either by thyroid hormone withdrawal for 4-6 weeks to achieve a TSH of ≥30, or by stimulation of remaining thyroid cells by recombinant human TSH (rhTSH) [ 4 ]. FDG PET has been shown to be useful in patients after surgery and ablation, who have recurrent

Article Type:
Case Report
DOI:
https://doi.org/10.1159/000360852
Volume/Issue:
Volume 3: Issue 2
Free access
Dong Jun Lim Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Korea

Search for other papers by Dong Jun Lim in
Google Scholar
PubMed Close
,
Won Bae Kim Department of Internal Medicine, Asan Medical Center, Korea

Search for other papers by Won Bae Kim in
Google Scholar
PubMed Close
,
Bo Hyun Kim Department of Internal Medicine, Pusan National University Hospital, Busan, Korea

Search for other papers by Bo Hyun Kim in
Google Scholar
PubMed Close
,
Tae Yong Kim Department of Internal Medicine, Asan Medical Center, Korea

Search for other papers by Tae Yong Kim in
Google Scholar
PubMed Close
,
Young Suk Jo Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea

Search for other papers by Young Suk Jo in
Google Scholar
PubMed Close
,
Ho-Cheol Kang Department of Internal Medicine, Chonnam National University Hospital, Gwangju, Korea

Search for other papers by Ho-Cheol Kang in
Google Scholar
PubMed Close
,
Young Joo Park Department of Internal Medicine, Seoul National University Hospital, Korea

Search for other papers by Young Joo Park in
Google Scholar
PubMed Close
,
Ka Hee Yi Department of Internal Medicine, Korea Cancer Center Hospital, Korea

Search for other papers by Ka Hee Yi in
Google Scholar
PubMed Close
,
Minho Shong Department of Internal Medicine, Chungnam National University Hospital, Daejeon, Korea

Search for other papers by Minho Shong in
Google Scholar
PubMed Close
,
In Joo Kim Department of Internal Medicine, Pusan National University Hospital, Busan, Korea

Search for other papers by In Joo Kim in
Google Scholar
PubMed Close
,
Do Joon Park Department of Internal Medicine, Seoul National University Hospital, Korea

Search for other papers by Do Joon Park in
Google Scholar
PubMed Close
,
Sun Wook Kim Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Sun Wook Kim in
Google Scholar
PubMed Close
,
Jae Hoon Chung Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Search for other papers by Jae Hoon Chung in
Google Scholar
PubMed Close
,
Jaetae Lee Department of Nuclear Medicine, Kyungpook National University Hospital, Daegu, Korea

Search for other papers by Jaetae Lee in
Google Scholar
PubMed Close
,
Sung-Soo Koong Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Korea

Search for other papers by Sung-Soo Koong in
Google Scholar
PubMed Close
, and
Young Kee Shong Department of Internal Medicine, Asan Medical Center, Korea

Search for other papers by Young Kee Shong in
Google Scholar
PubMed Close

patients and can result in a myriad of deleterious symptoms and impaired quality of life (QoL) [ 2 , 3 ]. According to the recent clinical practice guidelines, recombinant human TSH (rhTSH) can be used as an alternative to THW for remnant ablation or for

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000371512
Volume/Issue:
Volume 4: Issue 1
Free access
Steen J. Bonnema Departments of Endocrinology, Odense University Hospital, Odense

Search for other papers by Steen J. Bonnema in
Google Scholar
PubMed Close
,
Elisabeth S. Stovgaard Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Elisabeth S. Stovgaard in
Google Scholar
PubMed Close
,
Søren Fast Departments of Endocrinology, Odense University Hospital, Odense

Search for other papers by Søren Fast in
Google Scholar
PubMed Close
,
Kasper Broedbaek Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Kasper Broedbaek in
Google Scholar
PubMed Close
,
Jon T. Andersen Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Jon T. Andersen in
Google Scholar
PubMed Close
,
Allan Weimann Laboratory of Clinical Pharmacology Q7642, Rigshospitalet

Search for other papers by Allan Weimann in
Google Scholar
PubMed Close
,
Peter Grupe Departments of Nuclear Medicine, Odense University Hospital, Odense

Search for other papers by Peter Grupe in
Google Scholar
PubMed Close
,
Laszlo Hegedüs Departments of Endocrinology, Odense University Hospital, Odense

Search for other papers by Laszlo Hegedüs in
Google Scholar
PubMed Close
, and
Henrik E. Poulsen Laboratory of Clinical Pharmacology Q7642, Rigshospitalet
Department of Clinical Pharmacology, Bispebjerg Hospital
Faculty of Health Sciences, University of Copenhagen, Copenhagen, Denmark

Search for other papers by Henrik E. Poulsen in
Google Scholar
PubMed Close

Introduction For many years radioactive iodine ( 131 I) has been used for treatment of nontoxic goiter, hyperthyroidism and thyroid cancer. During the last decade recombinant human TSH (rhTSH) - a very potent stimulator of the thyroid 131 I

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000371883
Volume/Issue:
Volume 4: Issue 1
Free access
Carla Gambale Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy

Search for other papers by Carla Gambale in
Google Scholar
PubMed Close
,
Alessandro Prete Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy

Search for other papers by Alessandro Prete in
Google Scholar
PubMed Close
,
Lea Contartese Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy

Search for other papers by Lea Contartese in
Google Scholar
PubMed Close
,
Liborio Torregrossa Department of Surgical, Medical, Molecular Pathology and Critical Area, Anatomic Pathology Section, University Hospital of Pisa, Pisa, Italy

Search for other papers by Liborio Torregrossa in
Google Scholar
PubMed Close
,
Francesca Bianchi Department of Nuclear Medicine, University Hospital of Pisa, Pisa, Italy

Search for other papers by Francesca Bianchi in
Google Scholar
PubMed Close
,
Eleonora Molinaro Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy

Search for other papers by Eleonora Molinaro in
Google Scholar
PubMed Close
,
Gabriele Materazzi Department of Surgical, Medical, Molecular Pathology and Critical Area, Unit of Endocrine Surgery, University Hospital of Pisa, Pisa, Italy

Search for other papers by Gabriele Materazzi in
Google Scholar
PubMed Close
,
Rossella Elisei Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy

Search for other papers by Rossella Elisei in
Google Scholar
PubMed Close
, and
Antonio Matrone Department of Clinical and Experimental Medicine, Unit of Endocrinology, University Hospital of Pisa, Pisa, Italy

Search for other papers by Antonio Matrone in
Google Scholar
PubMed Close

pathologic factors, including the ATA class of risk. BiR/InR were defined according to ATA 2015 guidelines as follows: BiR in case of thyroglobulin value on levothyroxine therapy (LT4-Tg) ≥1 ng/mL or Tg peak after recombinant human TSH stimulation (rhTSH

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-23-0052
Volume/Issue:
Volume 12: Issue 6
Open access
Sandrine Donadio-Andréi Siamed'Xpress, Hôtel Technologique Morandat, Gardanne

Search for other papers by Sandrine Donadio-Andréi in
Google Scholar
PubMed Close
,
Karim Chikh Hospices Civils de Lyon, Lyon
CARMEN-INSERM U1060, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud - Charles Mérieux, Oullins
Société Française de Médecine Nucléaire, Groupe de Biologie Spécialisée, Centre Antoine Béclère, Paris

Search for other papers by Karim Chikh in
Google Scholar
PubMed Close
,
Christine Heuclin BioSIMS Technologies, Seine Biopolis II, Rouen

Search for other papers by Christine Heuclin in
Google Scholar
PubMed Close
,
Elisabetta Kuczewski Hospices Civils de Lyon, Lyon

Search for other papers by Elisabetta Kuczewski in
Google Scholar
PubMed Close
,
Anne Charrié Hospices Civils de Lyon, Lyon
CARMEN-INSERM U1060, Université Claude Bernard Lyon 1, Faculté de Médecine et de Maïeutique Lyon Sud - Charles Mérieux, Oullins
Société Française de Médecine Nucléaire, Groupe de Biologie Spécialisée, Centre Antoine Béclère, Paris

Search for other papers by Anne Charrié in
Google Scholar
PubMed Close
,
Anne-Sophie Gauchez Société Française de Médecine Nucléaire, Groupe de Biologie Spécialisée, Centre Antoine Béclère, Paris
Laboratoire du Service de Médecine Nucléaire, Centre Hospitalier de Chambéry, Chambéry
Pôle de Biologie, Centre Hospitalier et Universitaire de Grenoble
UMR-S INSERM 1037, Grenoble, France

Search for other papers by Anne-Sophie Gauchez in
Google Scholar
PubMed Close
, and
Catherine Ronin Siamed'Xpress, Hôtel Technologique Morandat, Gardanne

Search for other papers by Catherine Ronin in
Google Scholar
PubMed Close

]. In this study, we engineered cells with such a variant of the human α2,6-sialyltransferase [ 25 ] and produced a TSH calibrator with a high content in sialic acid designed herein as recombinant glycoengineered TSH (rgTSH). To solve discordances

Article Type:
Research Article
DOI:
https://doi.org/10.1159/000449463
Volume/Issue:
Volume 6: Issue 1
Free access
Nianting Ju Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Nianting Ju in
Google Scholar
PubMed Close
,
Liying Hou Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Liying Hou in
Google Scholar
PubMed Close
,
Hongjun Song Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Hongjun Song in
Google Scholar
PubMed Close
,
Zhongling Qiu Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Zhongling Qiu in
Google Scholar
PubMed Close
,
Yang Wang Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Yang Wang in
Google Scholar
PubMed Close
,
Zhenkui Sun Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Zhenkui Sun in
Google Scholar
PubMed Close
,
Quanyong Luo Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Quanyong Luo in
Google Scholar
PubMed Close
, and
Chentian Shen Department of Nuclear Medicine, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

Search for other papers by Chentian Shen in
Google Scholar
PubMed Close

recombinant human TSH (rh-TSH) because the use of rh-TSH has not been approved in China yet. Therefore, further research is still needed before adopting this strategy. Conclusion The results of this study found no statistical difference in RRA success

Article Type:
Research Article
Collections:
Thyroid cancer - clinical
DOI:
https://doi.org/10.1530/ETJ-22-0219
Volume/Issue:
Volume 12: Issue 4
Open access
James Magner Genzyme, a Sanofi company, Cambridge, Mass., USA

Search for other papers by James Magner in
Google Scholar
PubMed Close

independently, all published in 1988 [ 11 , 12 , 13 ]. The human TSH subunit gene sequences were essential for the preparation of recombinant human TSH, which is made in large bioreactors using Chinese hamster ovary cells, since the posttranslational

Article Type:
Review Article
DOI:
https://doi.org/10.1159/000360534
Volume/Issue:
Volume 3: Issue 2
Free access
Furio Pacini Department of Internal Medicine, Endocrinology and Metabolism and Biochemistry, Section of Endocrinology and Metabolism, University of Siena, Siena, Italy

Search for other papers by Furio Pacini in
Google Scholar
PubMed Close

Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ: Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone

Article Type:
Editorial
DOI:
https://doi.org/10.1159/000346154
Volume/Issue:
Volume 1: Issue 4
Free access